In recently performed pilot experiments in an ovarian cancer metastatic model, systemic intraperitoneal application of M002 resulted in a robust tumor-antigen specific CD8+ T cell response in the peritoneal cavity and the omentum [97], which are the primary sites of ovarian cancer metastasis [98]. Here, CD8A is linked to neoplasm.